A comprehensive analysis of private equity and venture capital activity across AI-enabled healthcare companies — deal flow, valuation trends, sector composition, and forward outlook.
The AI healthcare investment landscape reached a decisive inflection point in 2025. After years of speculation, capital is now flowing with conviction toward companies that demonstrate measurable clinical and operational impact — not merely technological novelty.
U.S. digital health startups raised $14.2 billion in 2025, a 35% increase from 2024's $10.5 billion and the strongest annual figure in three years. Critically, this growth was not broad-based: deal count actually fell from 509 to 482, while average deal size climbed from $20.7M to $29.3M. Capital is concentrating rapidly.
AI-enabled companies captured 54% of total funding, up dramatically from 37% in 2024. These companies commanded a 19% premium on average deal size, and at the mega-deal tier ($100M+), AI firms claimed 9 of 11 rounds — representing 42% of all investment dollars.
The era of speculative digital health investing is over. Investors — particularly the megafunds whose participation dramatically amplifies round sizes — are now requiring peer-reviewed validation, clear paths to profitability, and evidence of rapid provider adoption before committing capital.
This "fundamentals-first" environment has bifurcated the market sharply. The top quartile of companies attracted outsized rounds at speed; 35% of all 2025 deals were flat or down rounds, and unlabeled bridge financing remained elevated at 34% of deal count. Many companies from the 2020-2021 vintage are still working through valuation overhangs.
Source: Rock Health 2025 Annual Report. Note: 2021 peak reflects pandemic-era speculative environment.
The following represents the largest and most strategically significant funding rounds closed by AI healthcare companies during 2025, sourced from Rock Health, Crunchbase, and sector reports.
| Company | Amount | Lead Investor(s) | Sector | Model |
|---|---|---|---|---|
|
Oura
AI-powered wearable health monitoring ring
Series E
|
$900M | Undisclosed | Clinical | B2CDirect-to-consumer wearable |
|
Strive Health
AI-enabled kidney care management platform
Series D
|
$550M | Undisclosed | Clinical | B2BSells to payers & health systems |
|
Abridge
AI clinical documentation & ambient scribe (two rounds)
Series D + Series E
|
$550M | Various; $5.3B valuation (Series E) | Admin | B2BSells to health systems & hospitals |
|
Judi Health
Health tech & pharmacy benefit administration
Series F
|
$400M | Undisclosed | Admin | B2BSells to employers & payers |
|
Lila Sciences
Scientific superintelligence platform for drug discovery
Seed + Series A (×3 rounds)
|
$550M | General Catalyst, Flagship Pioneering, NVentures; $1.3B val. | Drug Dev. | B2BPlatform licensed to pharma & biotech |
|
Truveta
World's largest real-world health data platform for drug discovery
Growth Round
|
$320M | Health system consortium | Data | B2BData sold to pharma & researchers |
|
Abridge
AI clinical documentation — Series E (standalone)
Series E
|
$300M | Undisclosed; $5.3B valuation | Admin | B2BSells to health systems & hospitals |
|
Function Health
Comprehensive lab testing and AI health insights
Series B
|
$298M | Undisclosed | Diagnostics | B2CMembership sold direct to consumer |
|
Innovaccer
AI healthcare cloud — data platform & analytics
Series F
|
$275M | Undisclosed (January 2025) | Data | B2BSells to health systems & ACOs |
|
Ambience Healthcare
AI operating system for healthcare documentation
Series C
|
$243M | Undisclosed | Admin | B2BSells to clinics & health systems |
|
OpenEvidence
AI-powered clinical decision support & search for physicians
Series B
|
$210M | Undisclosed; $3.5B valuation | Clinical | B2B2CFree to physicians; monetizes via pharma & institutions |
|
Commure
Ambient AI platform for healthcare automation
Growth Financing
|
$200M | Undisclosed | Admin | B2BSells to health systems & clinics |
|
Hippocratic AI
Safety-first LLMs for non-diagnostic healthcare tasks
Series C
|
$126M | General Catalyst, Andreessen Horowitz, NVentures; $1.64B val. | Clinical | B2BSells to payers, providers & pharma |
|
Duos
AI-powered member activation & benefits execution
Strategic Growth Equity
|
$130M | FTV Capital (October 2025) | Admin | B2BSells to Medicare Advantage plans |
|
Honest Health
AI-enabled tech tools for primary care providers
Growth Financing
|
$140M | NewSpring (lead) | Clinical | B2BSells to independent primary care practices |
Source: Rock Health H1 2025 Funding Report
AI-enabled companies commanded an 83% premium on average deal size vs. non-AI peers across all stages.
Private equity has moved beyond observation into active deal-making, deploying a distinct roll-up strategy: combining AI-native capabilities with legacy healthcare services platforms to drive simultaneous revenue growth and margin expansion.
New Mountain Capital executed one of the most significant AI healthcare PE transactions of 2025, combining Access Healthcare (a revenue cycle management and business process outsourcing firm) with the clinical AI technology of SmarterDx and Thoughtful.ai to form Smarter Technologies. The firm subsequently acquired Machinify, weaving its AI capabilities into a combined entity that also included legacy payment integrity providers Apixio, Varis, and The Rawlings Group. This transaction exemplifies the "AI-native + legacy infrastructure" roll-up thesis gaining traction across PE strategies.
Waystar's strategic acquisition of Iodine — a clinical AI company focused on revenue integrity and documentation improvement — represents the "layered cake strategy" Bessemer Venture Partners has identified as the dominant M&A rationale. Rather than a speculative bet on future AI value, Waystar sought to own AI capabilities delivering immediate margin improvement rather than build them from scratch.
Armed with $275 million in Series F funding, Innovaccer acquired Story Health — a startup helping providers care for patients with heart failure. This illustrates the bifurcated M&A market: well-capitalized AI platforms acquiring cash-starved but clinically validated startups that raised last in 2022, unable to access 2025's difficult VC environment for earlier-stage companies.
M&A deals in H1 2025 alone — on pace to nearly double the 121 deals recorded in all of 2024.
Global health tech M&A deals in 2025, up from 350 in 2024. PE firms recognize AI simultaneously drives revenue growth and margin expansion.
Rise in M&A activity in 2025, per Visible.vc analysis, making strategic acquisition increasingly the primary exit path as IPO markets remain selective.
2025 marked the reopening of the digital health IPO window after a two-year near-total drought. Five companies reached public markets, adding $36.6 billion in combined market capitalization — all with strong unit economics and demonstrated profitability trajectories.
AI ambient scribes — technology that automatically documents clinical encounters — has achieved 30–40% physician adoption rates, with leading health systems reporting up to 90% utilization. Rock Health characterizes this as faster adoption than any other technology in healthcare history. Abridge ($550M), Ambience Healthcare ($243M), and Commure ($200M) are the principal beneficiaries.
Generative AI's ability to compress the drug discovery timeline is attracting serious capital. Lila Sciences raised $550M across three rounds in seven months at a $1.3B valuation. Investors include Flagship Pioneering and General Catalyst — both with deep healthcare conviction. GV and Alphabet participation signals long-horizon bets on platform-level value creation.
AI applied to revenue cycle management, prior authorization, and claims processing creates defensible, recurring revenue streams with clear ROI — ideal for PE roll-up strategies. New Mountain Capital's Smarter Technologies consolidation and Waystar's Iodine acquisition both target this theme. Gross margin expansion is demonstrable within 12 months of AI integration.
35% of 2025 deals were flat or down rounds. Unlabeled bridge financings remain elevated at 34% — a proxy for distress. Companies from the 2020–2021 vintage carrying valuation overhangs face difficult choices: strategic sale (often at a discount), bridge financing, or dilutive resets. This creates both risk for existing LPs and opportunity for patient new capital.
The Trump administration's Medicaid reform agenda, evolving AI transparency requirements, and the SEC filing backlog following the 2025 government shutdown create material near-term uncertainty. Digital health companies with significant Medicaid-reimbursed revenue face coverage cliff risks. AI algorithmic accountability regulation is emerging as a distinct compliance burden.
Several AI healthcare companies raised multiple large rounds in compressed timeframes (e.g., Lila Sciences: $550M across three rounds in seven months). Rock Health flags this as carrying inherent risk: insufficient time between rounds to demonstrate meaningful commercial progress increases the probability of future valuation pressure or bridge dependency.
Agentic AI — systems capable of autonomously navigating complex insurance rules, clinical protocols, and prior authorization workflows — is the most significant emerging investment theme. Investors are moving from simple task automation to multi-step autonomous agents that operate end-to-end within healthcare workflows. Capital is concentrating at this frontier.
The "trust gap" between health tech fundamentals and public market valuations is expected to narrow over 12–24 months as the second-generation cohort of public companies (Hinge Health, HeartFlow, Waystar, Tempus) builds a sustained track record. Bessemer projects this gap closure could unlock significantly higher valuation multiples for the category.
IPO candidates Aledade, Maven Clinic, Virta Health, and Zelis are being watched closely. Policy and macro conditions, including Medicaid reform uncertainty, represent the primary gatekeeping variable on timing.
Basis Points Health is an independent quarterly publication tracking private equity and venture capital investment into AI-native healthcare companies. We write for operators, investors, and strategists who need the signal without the noise.
We are not affiliated with any investment fund, healthcare system, or technology vendor. No company pays to appear in our deal register or investment thesis sections. Our editorial positions reflect our own analysis of publicly available data and industry reporting.
Each issue covers one full quarter of deal activity — funding rounds, PE transactions, M&A, and public market exits — with a consistent analytical framework that makes issues comparable over time. We believe the healthcare AI market is large enough and fast-moving enough that a rigorous, design-quality quarterly record is genuinely useful.
LPs, GPs, and family offices tracking the healthcare AI category across venture and PE. Use this as a quarterly deal log and market temperature check alongside your own sourcing.
AI healthcare startup founders tracking competitive funding, comparable valuations, and which investors are active in your category. Understanding the capital landscape is part of running the business.
Corporate development and strategy teams at health systems, payers, and pharma companies tracking which AI companies are attracting capital and why — and what that signals about where the market is going.
A curated, design-quality primary reference for the healthcare AI funding landscape — with deal data, sector breakdowns, and investment thesis analysis in one place.
Every deal in the register meets a defined set of criteria. We publish these openly so readers can assess what is and isn't included — and flag anything we may have missed.
| Criterion | Our Standard | Rationale |
|---|---|---|
| Minimum Round Size | $100M+ for full deal register entry; $25M+ tracked but not individually profiled | Below $25M, deals are numerous and signal is low. We track the full market but profile only rounds large enough to indicate conviction at fund scale. |
| AI Definition | Company must use machine learning, large language models, computer vision, or predictive analytics as a core product component — not merely as a back-end feature | We exclude companies that use AI incidentally (e.g., basic analytics dashboards) and include only those where AI is a primary value driver. Borderline cases are noted. |
| Geographic Scope | U.S.-headquartered or U.S.-listed companies; global rounds involving a U.S. lead investor are noted separately | Reimbursement environments, regulatory frameworks, and exit markets differ significantly. U.S.-focus allows like-for-like comparison across issues. |
| Data Sources | Rock Health annual and mid-year reports; Crunchbase; company press releases; SEC filings; STAT News, Fierce Healthcare, Healthcare Brew, and BioPharma Dive coverage | We triangulate across at least two sources for every round above $100M. Figures represent announced amounts; undisclosed tranches are noted. |
| Valuation Figures | Post-money valuations reported only when publicly disclosed by company or investor | We do not estimate or model valuations. Undisclosed valuations are left blank rather than approximated. |
| Business Model Classification | B2B (sells to organizations), B2C (sells direct to consumers), B2B2C (free or subsidized to end user; monetizes via enterprise), B2G (sells to government/CMS) | Model classification matters for margin structure, sales cycle, and exit comparables. Classifications reflect primary revenue model at time of round. |
| What We Exclude | Pure biotech / therapeutics without a software AI component; medical device companies without an AI data layer; health insurance carriers; hospital systems raising capital | These segments have distinct valuation frameworks, investor bases, and exit markets. Mixing them with AI software companies distorts category-level analysis. |
See something missing or incorrect? We welcome corrections. Contact details will be published with our second issue.
The regulatory and reimbursement environment is the single most important external variable for AI healthcare investment returns. This tracker covers the key FDA, CMS, and legislative developments as of Q1 2026.
| Item | Detail | Status |
|---|---|---|
| FDA AI/ML-Based SaMD Action PlanOngoing software-as-medical-device framework | FDA has cleared over 950 AI/ML-enabled medical devices as of early 2026, with radiology and cardiology comprising the largest share. The agency is developing a predetermined change control plan framework allowing iterative AI model updates without full re-clearance — a major unlock for SaMD companies. | In Progress |
| CMS Reimbursement: AI-Assisted DiagnosticsCoverage for AI radiology CADe/CADx tools | CMS finalized reimbursement codes for AI-assisted colonoscopy (CPT 0723T) and continues to expand coverage for AI-assisted imaging analysis. Reimbursement parity with traditional diagnostics remains the key bottleneck for AI diagnostics adoption at scale. | Active |
| ONC HTI-1 Rule — TEFCA & InteroperabilityHealth data sharing requirements | The ONC's HTI-1 final rule, effective 2024–2025, expands information blocking prohibitions and accelerates TEFCA implementation. For AI companies dependent on EHR data access, this materially reduces friction in data acquisition — a structural tailwind for clinical AI platforms. | Passed |
| Prior Authorization Reform (CMS Final Rule)Mandatory payer PA timeline reductions | CMS finalized rules requiring payers to respond to prior authorization requests within 72 hours (urgent) and 7 days (standard) by 2026. This creates immediate commercial urgency for AI prior authorization automation vendors — a direct catalyst for companies like Cohere Health, Hippocratic AI, and similar. | Active 2026 |
| Medicaid Unwinding & Reform RiskTrump administration restructuring | The administration's Medicaid restructuring proposals — including per-capita caps and work requirements — create material revenue risk for AI companies whose payer customers are heavily Medicaid-exposed. This is the most significant near-term policy headwind in the sector. Extent of implementation remains uncertain as of Q1 2026. | Uncertain |
| EU AI Act — Healthcare ProvisionsHigh-risk AI classification for medical AI | The EU AI Act classifies most clinical AI as "high-risk," requiring conformity assessments, post-market monitoring, and transparency obligations. U.S. companies planning European expansion face meaningful compliance overhead. For pure-play U.S. companies, near-term impact is limited — but global ambitions carry regulatory cost. | In Force 2025 |
| HIPAA AI Amendment ProposalsAI-specific data use and consent rules | HHS has signaled interest in HIPAA amendments addressing AI training data use, de-identification standards for LLM training, and patient consent requirements for AI-assisted care decisions. No final rule as of Q1 2026, but proposed guidance is expected. This is a material watch item for companies training models on patient data. | Proposed |
A complete picture of the market requires accounting for both sides of the ledger. The following documents the most significant digital health shutdowns, distressed sales, and acqui-hires from the 2024–2025 period — many of them 2021-vintage companies that could not sustain their raise pace in a tighter funding environment.
We intend to expand failures and distress coverage in future issues as we build our tracking methodology. If you are aware of shutdowns, acqui-hires, or significant down rounds we should be tracking, we welcome tips. Contact information will be published with Issue No. 2.
Rock Health 2025 Annual Funding Report (January 2026); Rock Health H1 2025 Mid-Year Report (July 2025); Bessemer Venture Partners State of Health AI 2026 (January 2026); SVB Healthcare Investments & Exits Report 2026.
Crunchbase Sector Snapshot: AI Healthcare (November 2025); Fierce Healthcare digital health coverage (2025); Healthcare Brew Top 20 Rounds (December 2025); BioPharma Dive funding analysis; AHA Center for Health Innovation; STAT News M&A coverage.
Individual deal figures sourced from company press releases and public filings where available. Round sizes represent announced figures; valuations represent publicly disclosed post-money valuations. Some deals may include undisclosed investors or tranches.
Basis Points Health lands in your inbox four times a year — covering the biggest funding rounds, PE moves, IPO activity, and the investment theses driving capital into AI-native healthcare. No noise, no daily emails. Just the quarterly signal.
Quarterly cadence · No spam · Unsubscribe anytime · Email provider TBD
Each issue of Basis Points Health covers one quarter of AI healthcare investment activity. All past reports remain freely accessible below — no paywall, no login.
IMPORTANT DISCLAIMER: This report is prepared for informational and discussion purposes only and does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security. The information contained herein has been obtained from sources believed to be reliable, but its accuracy and completeness cannot be guaranteed. Past performance is not indicative of future results.
All figures are sourced from publicly available industry reports and company announcements as of March 2026. Market data may have changed since publication. This document is
© 2026 Basis Points Health. All rights reserved. Reproduction without express written permission is prohibited. Report compiled March 18, 2026.